353235-01-5
353235-01-5
Chemical Structure
CBiPES
- CAS No.: 353235-01-5
- Formula:C21H19N3O2S
- Molecular Weight:377.46
InChIKey: HDVYXILCBYGKGU-UHFFFAOYSA-N
SMILES: CCS(N(C1=CC(C2=CC=C(C#N)C=C2)=CC=C1)CC3=CN=CC=C3)(=O)=O
Biological Activity: CBiPES is a potent mGlu2 positive allosteric modulator with an EC50 value of 92.8 nM. CBiPES attenuates stress-induced hyperthermia and Phencyclidine-induced hyperlocomotor activity. CBiPES can be used for research of neurological diseases, such as Parkinson's disease (PD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CBiPES | 99.74% | CBiPES is a potent mGlu2 positive allosteric modulator with an EC50 value of 92.8 nM. CBiPES attenuates stress-induced hyperthermia and Phencyclidine-induced hyperlocomotor activity. CBiPES can be used for research of neurological diseases, such as Parkinson's disease (PD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CBiPES (Standard) | CBiPES (Standard) is the analytical standard of CBiPES (HY-107505A). This product is intended for research and analytical applications. CBiPES is a potent mGlu2 positive allosteric modulator with an EC50 value of 92.8 nM. CBiPES attenuates stress-induced hyperthermia and Phencyclidine-induced hyperlocomotor activity. CBiPES can be used for research of neurological diseases, such as ParKinson's disease (PD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Johnson MP, et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl). 2005 Apr;179(1):271-83. [Content Brief]
- [2]. Frouni I, et al. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. J Neural Transm (Vienna). 2021 Jan;128(1):73-81. [Content Brief]
